|
|||||||||||||||||||||||||
|
WednesdayClinical studies still overlook gender difference, which leaves women at a disadvantage and could endanger their health, according to a new report
It's been more than 20 years since legislators mandated that clinical trials funded by the National Institutes of Health include women and minorities, but disease and drug studies often involve more men than women and don't break down the results by gender, according to the report. This information is crucial, especially when dealing with cardiovascular disease--the top cause of death among women in America--as well as depression, Alzheimer's disease and lung cancer, which all manifest in and affect women differently than men.
"Women are now routinely included in clinical trials, but we are far from achieving equity in biomedical research," report leader Paula Johnson, M.D., executive director of the Connors Center, told the Boston Globe.
For example, women's cardiovascular disease mortality rates decrease more slowly than men's, and the number of cardiovascular disease deaths for women with diabetes increased 23 percent. Yet only 35 percent of clinical trial cardiovascular research subjects are women, and only 31 percent of related studies report outcomes by sex, according to the report.
"If medical research is skewed to male physiology, women are at risk for incorrect diagnoses and inadequate treatment recommendations and missed opportunities for prevention," Jill Goldstein, Ph.D., director of research at the Connors Center, told the Boston Herald.
The report called for healthcare agencies and organizations to push for equality when it comes to gender research by:
|